Results 71 to 80 of about 5,080,573 (227)

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

CD5– Mantle Cell Lymphoma [PDF]

American Journal of Clinical Pathology, 2002
Mantle cell lymphoma (MCL) typically expresses B-cell antigens and CD5 and overexpresses bcl-1 protein. However, unusual cases of bcl-1+ and CD5-MCL have been observed, posing a practical challenge for correct diagnosis and management. We identified 25 cases (48 samples) of bcl-1+ and CD5- lymphoma.
Zach, Liu, Henry Y, Dong, Wojciech, Gorczyca, Patricia, Tsang, Patti, Cohen, Christine F, Stephenson, Carol S, Berger, C Daniel, Wu, James, Weisberger   +8 more
openaire   +2 more sources

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Molecular Pathogenesis of MALT lymphoma [PDF]

, 2011
Mucosa associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the NF-κB pathway.

core   +2 more sources

Acute dyspnoea and single tracheal localisation of mantle cell lymphoma

Journal of Hematology & Oncology, 2010
Background Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis. Few other mucosal infiltrations have been already reported. Results
Quintin-Roué Isabelle, Morel Frederic, André Norbert, Eveillard Jean-Richard, Tempescul Adrian, Ianotto Jean-Christophe, Berthou Christian   +6 more
doaj   +1 more source

Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop [PDF]

Leukemia & Lymphoma, 2010
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically characterized by cyclin D1 overexpression as result of the t(11;14) translocation. MCL is biologically and clinically heterogeneous and frequently involves extranodal dissemination.
Michael E, Williams, Joseph M, Connors, Martin H, Dreyling, Randy D, Gascoyne, Brad S, Kahl, John P, Leonard, Oliver W, Press, Wyndham H, Wilson   +7 more
openaire   +2 more sources

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR‐Mutated Lung Cancer

Cancer Science, EarlyView.
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Yu Zhao, Yuqiang Liu, Mingxuan Xie, Zhiming Ye, Hong Huang, Maojin Yao, Feng Zhou, Jianzhu Zhao, Jun Tang   +8 more
wiley   +1 more source

Skin manifestation of mantle cell lymphoma – case report and literature review [PDF]

, 2017
Mantle cell lymphoma is a rare neoplastic disease of the lymphatic system derived from mature B lymphocytes. It very commonly affects extranodal sites including the bone marrow, gastrointestinal tract and Waldeyer’s ring, but skin involvement is seen ...
Natalia Zdanowska, Agnieszka Markiewicz, Waldemar J. Placek, Mateusz M. Markiewicz, Agnieszka B. Owczarczyk-Saczonek, Dawid Sigorski   +5 more
core   +1 more source

Aberrant Expression of Multiple T‐Cell Markers in Primary Cutaneous Follicle Center Lymphoma: A Rare Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Aberrant expression of T‐cell markers in B‐cell lymphomas is rare and can pose diagnostic challenges. We report a case of a 65‐year‐old man presenting with newly developed scalp nodules. Histopathology revealed nodular lymphoid infiltrates composed of large centrocytes and centroblasts.
V. Pfefferle, A. Vogelsberg, M. Maaß, C. M. Schürch, S. Forchhammer   +4 more
wiley   +1 more source